Evidence map›Paper›PMID 36112723›Full record

ArticleJornal brasileiro de nefrologia

Use of probiotics in patients with chronic kidney disease on hemodialysis: a randomized clinical trial.

Érica Maria Rodrigues de Araújo, Gdayllon Cavalcante Meneses, Antônio Augusto Ferreira Carioca, Alice Maria Costa Martins, Elizabeth De Francesco Daher, Geraldo Bezerra Silva Junior

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Jornal brasileiro de nefrologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06863194 (Effects of Probiotic Supplementation on Disease Progression in Patients With Moderate to Severe Chronic Kidney Disease), which is not on this map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06863194 phase1 / phase2recruitingnot on this map

Effects of Probiotic Supplementation on Disease Progression in Patients With Moderate to Severe Chronic Kidney Disease: A Randomized Controlled Trial

TypeinterventionalSponsorMansoura UniversityRan2025 to 2025Enrolled72ConditionsKidney Disease, Chronic, Renal Insufficiency, Chronic, Gut Dysbiosis, Uremic ToxinsArmsProbiotic Supplementation (Lactobacillus plantarum), Placebo Tablets
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Safety ofNutrients · 2026
    Trial
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Probiotics in CKD: waiting for the evidence.Jornal brasileiro de nefrologia
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Érica Maria Rodrigues de AraújoUniversidade de Fortaleza, Programa de Pós-Graduação em Ciências Médicas, Fortaleza, CE, Brazil.ORCID 0000-0002-1686-5274
Gdayllon Cavalcante MenesesUniversidade de Fortaleza, Programa de Pós-Graduação em Ciências Médicas, Fortaleza, CE, Brazil.ORCID 0000-0002-0160-5728
Antônio Augusto Ferreira CariocaUniversidade de Fortaleza, Curso de Nutrição e Programa de Pós-Graduação em Saúde Coletiva, Fortaleza, CE, Brazil.ORCID 0000-0002-1194-562X
Alice Maria Costa MartinsUniversidade Federal do Ceará, Programas de Pós-Graduação em Farmacologia e Ciências Farmacêuticas, Fortaleza, CE, Brazil.ORCID 0000-0001-8160-2027
Elizabeth De Francesco DaherUniversidade Federal do Ceará, Faculdade de Medicina, Programa de Pós-graduação em Ciências Médicas, Departamento de Medicina Clínica, Fortaleza, CE, Brazil.ORCID 0000-0003-4189-1738
Geraldo Bezerra Silva JuniorUniversidade de Fortaleza, Programa de Pós-Graduação em Ciências Médicas, Fortaleza, CE, Brazil.ORCID 0000-0002-8971-0994

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSupplementation with probiotics for patients with chronic kidney disease (CKD) may be associated with decreased systemic inflammation.

objectiveTo assess the impact of oral supplementation with probiotics for patients with CKD on hemodialysis.

methodThis double-blind randomized clinical trial included 70 patients on hemodialysis; 32 were given oral supplementation with probiotics and 38 were in the placebo group. Blood samples were collected at the start of the study and patients were given oral supplementation with probiotics or placebo for three months. The probiotic supplement comprised four strains of encapsulated Gram-positive bacteria: Lactobacillus Plantarum A87, Lactobacillus rhamnosus, Bifidobacterium bifidum A218 and Bifidobacterium longum A101. Patients were given one capsule per day for 3 months. Blood samples were taken throughout the study to check for inflammatory biomarkers. Non-traditional biomarkers Syndecan-1, IFN-y, NGAL, and cystatin C were measured using an ELISA kit, along with biochemical parameters CRP, calcium, phosphorus, potassium, PTH, GPT, hematocrit, hemoglobin, glucose, and urea.

resultsPatients given supplementation with probiotics had significant decreases in serum levels of syndecan-1 (239 ± 113 to 184 ± 106 ng/mL, p = 0.005); blood glucose levels also decreased significantly (162 ± 112 to 146 ± 74 mg/dL, p = 0.02).

conclusionAdministration of probiotics to patients with advanced CKD was associated with decreases in syndecan-1 and blood glucose levels, indicating potential improvements in metabolism and decreased systemic inflammation.

Identifiers

PMID36112723
PMCPMC10627128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.